1,1-dimethylethyl (2S)-2-(2-propyn-1-yl)-1-pyrrolidinecarboxylate | 1194056-48-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1,1-dimethylethyl (2S)-2-(2-propyn-1-yl)-1-pyrrolidinecarboxylate
• 英文别名: tert-butyl (S)-2-(prop-2-yn-1-yl)pyrrolidine-1-carboxylate；tert-butyl (S)-2-(prop-2-ynyl)pyrrolidine-1-carboxylate；(2S)-N-(tert-butoxycarbonyl)-2-(propargyl)pyrrolidine；tert-butyl (2S)-2-prop-2-ynylpyrrolidine-1-carboxylate
• CAS: 1194056-48-8
• 化学式: C₁₂H₁₉NO₂
• 分子量: 209.288
• InChiKey: JGDWMYNRMVUNMO-SNVBAGLBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,1-dimethylethyl (2S)-2-(2-propyn-1-yl)-1-pyrrolidinecarboxylate 在 正丁基锂 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 1.67h， 生成
  参考文献：
  名称：

  The design of 8-hydroxyquinoline tetracyclic lactams as HIV-1 integrase strand transfer inhibitors

  摘要：

  A novel series of HIV-1 integrase strand transfer inhibitors were designed using the venerable two-metal binding pharmacophore model and incorporating structural elements from two different literature scaffolds. This manuscript describes a number of 8-hydroxyquinoline tetracyclic lactams with exceptional antiviral activity against HIV-1 and little loss of potency against the IN signature resistance mutations Q148K and G140S/Q148H. (C) 2016 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2016.03.038
• 作为产物：
  描述：

  diethyl 1-diazo-2-oxopropylphosphonate 、 tert-butyl (2S)-2-(2-oxoethyl)pyrrolidine-1-carboxylate 在 甲醇 、 potassium carbonate 作用下， 反应 2.0h， 生成 1,1-dimethylethyl (2S)-2-(2-propyn-1-yl)-1-pyrrolidinecarboxylate
  参考文献：
  名称：

  The design of 8-hydroxyquinoline tetracyclic lactams as HIV-1 integrase strand transfer inhibitors

  摘要：

  A novel series of HIV-1 integrase strand transfer inhibitors were designed using the venerable two-metal binding pharmacophore model and incorporating structural elements from two different literature scaffolds. This manuscript describes a number of 8-hydroxyquinoline tetracyclic lactams with exceptional antiviral activity against HIV-1 and little loss of potency against the IN signature resistance mutations Q148K and G140S/Q148H. (C) 2016 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2016.03.038

文献信息

• Pharmaceutical compositions and methods for use
  申请人：——

  公开号：US20020058652A1

  公开（公告）日：2002-05-16

  The present invention relates to aryl olefinic azacyclic compounds and aryl acetylenic azacyclic compounds, including pyridyl olefinic cycloalkylamines and pyridyl acetylenic cycloalkylamines. The present invention also relates to prodrug derivatives of the compounds of the present invention.

  本发明涉及芳基烯丙基氮杂环化合物和芳基炔丙基氮杂环化合物，包括吡啶基烯丙基环烷基胺和吡啶基炔丙基环烷基胺。本发明还涉及本发明化合物的药物前体衍生物。
• [EN] FIVE-MEMBERED HETEROAROMATIC OLEFINIC AZACYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS INHIBITORS OF NCOTINIC CHOLINERGIC RECEPTORS<br/>[FR] COMPOSES HETEROAROMATIQUES OLEFINIQUES AZACYCLIQUES A CINQ ELEMENTS, COMPOSITIONS PHARMACEUTIQUES CONTENANT LESDITS COMPOSES ET LEUR UTILISATION COMME INHIBITEURS DES RECEPTEURS NICOTINIQUES CHOLINERGIQUES
  申请人：TARGACEPT INC

  公开号：WO2004009599A1

  公开（公告）日：2004-01-29

  The present invention relates to five-membered heteroaromatic olefinic azacyclic compounds and five-membered heteroaromatic acetylenic azacylic compounds, having formula (I) wherein the ring including X, XI, XII, XIII and X IV is heteroaromatic, B is a two-carbon bridging species and Q, E, EI, EII, EIII, m and n are as defined herein and pharmaceutical compositions containing them that are capable of affecting nicotic cholinergic receptors.

  本发明涉及五元杂芳烯基氮杂环化合物和五元杂芳乙炔基氮环化合物，其化学式为（I），其中包括X、XI、XII、XIII和XIV的环是杂芳环，B是一个含有两个碳的桥联物种，Q、E、EI、EII、EIII、m和n的定义如本文所述，并含有这些化合物的药物组合物，能够影响烟碱型胆碱受体。
• [EN] QUINOLINE CGAS ANTAGONIST COMPOUNDS<br/>[FR] COMPOSÉS DE QUINOLÉINE ANTAGONISTES DE CGAS
  申请人：IMMUNESENSOR THERAPEUTICS INC

  公开号：WO2022051634A1

  公开（公告）日：2022-03-10

  The present disclosure provides compounds that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

  本公开提供了一种cGAS拮抗剂化合物，制备这些化合物的方法，含有这些化合物的药物组合物，以及它们在医学治疗中的用途。
• [EN] ANTIBACTERIAL FLUOROQUINOLONE ANALOGS<br/>[FR] ANALOGUES DE FLUOROQUINOLONE ANTIBACTÉRIENS
  申请人：ACHAOGEN INC

  公开号：WO2011031745A1

  公开（公告）日：2011-03-17

  Compounds having antibacterial activity are disclosed. The compounds have one of the following structures (I)-(X): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein A, B, D, E, G, R1, R2, R3, R4, R5, R6, R7, R9 and R10are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  揭示了具有抗菌活性的化合物。这些化合物具有以下结构之一（I）-（X）：包括立体异构体，药学上可接受的盐和前药，其中A，B，D，E，G，R1，R2，R3，R4，R5，R6，R7，R9和R10如本文所定义。还揭示了与制备和使用这些化合物相关的方法，以及包含这些化合物的制药组合物。
• ANTIBACTERIAL FLUOROQUINOLONE ANALOGS
  申请人：Wagman Allan S.

  公开号：US20120058989A1

  公开（公告）日：2012-03-08

  Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein A, B, D, E, G, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  本发明公开了具有抗菌活性的化合物。该化合物具有以下结构（I）：包括立体异构体、药学上可接受的盐和前药，其中A、B、D、E、G、R1、R2、R3、R4、R5、R6和R7如本文所定义。本发明还公开了与制备和使用这种化合物相关的方法，以及包含这种化合物的制药组合物。